{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:32:28Z","timestamp":1763389948565,"version":"3.33.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"School level scientific research project of Xiangnan University","award":["2022JX128"],"award-info":[{"award-number":["2022JX128"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-85650-7","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:21:48Z","timestamp":1736965308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of changes in the chemokine CXC ligand 13 in serum and cerebrospinal fluid of patients with neuromyelitis optica"],"prefix":"10.1038","volume":"15","author":[{"given":"Juan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"1","key":"85650_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy, M., Fujihara, K. & Palace, J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 20(1), 60\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(20)30392- (2021).","journal-title":"Lancet Neurol."},{"issue":"1","key":"85650_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ncl.2020.09","volume":"39","author":"AI Wallach","year":"2021","unstructured":"Wallach, A. I., Tremblay, M. & Kister, I. Advances in the treatment of neuromyelitis optica spectrum disorder. Neurol. Clin. 39(1), 35\u201349. https:\/\/doi.org\/10.1016\/j.ncl.2020.09 (2021).","journal-title":"Neurol. Clin."},{"key":"85650_CR3","doi-asserted-by":"publisher","unstructured":"Dutra, B. G. et al. Neuromyelitis optica spectrum disorders: Spectrum of MR imaging findings and their differential diagnosis. Radiographics. https:\/\/doi.org\/10.1148\/rg.2018170141 (2018). Erratum in: Radiographics. 2018;38(2):662.  38(1):169\u2013193.","DOI":"10.1148\/rg.2018170141"},{"issue":"6","key":"85650_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neurol.2018.02.084","volume":"174","author":"C Alves Do Rego","year":"2018","unstructured":"Alves Do Rego, C. & Collongues, N. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev. Neurol. (Paris). 174(6), 458\u2013470. https:\/\/doi.org\/10.1016\/j.neurol.2018.02.084 (2018).","journal-title":"Rev. Neurol. (Paris)"},{"key":"85650_CR5","doi-asserted-by":"crossref","unstructured":"Jarius, S., Paul, F., Weinshenker, B.G., Levy, M., Kim, H.J., Wildemann, B. Neuromyelitis optica. Nat. Rev. Dis. Primers. 6(1), 85 (2020).","DOI":"10.1038\/s41572-020-0214-9"},{"issue":"7","key":"85650_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S1474-4422(20)30184-8","volume":"19","author":"FS Brown","year":"2020","unstructured":"Brown, F. S. Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder. Lancet Neurol. 19(7), 564. https:\/\/doi.org\/10.1016\/S1474-4422(20)30184-8 (2020).","journal-title":"Lancet Neurol."},{"key":"85650_CR7","doi-asserted-by":"publisher","unstructured":"Simaniv, T. O. et al. Optikone\u012dromielita [Neuromyelitis optica and neuromyelitis optica spectrum disorders]. Zh Nevrol Psikhiatr Im SS Korsakova 119(10. Vyp. 2), 35\u201348 https:\/\/doi.org\/10.17116\/jnevro20191191035 (2019). Russian.","DOI":"10.17116\/jnevro20191191035"},{"issue":"5","key":"85650_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.11477\/mf.1416201779","volume":"73","author":"T Matsushita","year":"2021","unstructured":"Matsushita, T. Corticosteroid therapy in patients with Autoimmune diseases of the Central Nervous System. Brain Nerve. 73(5), 408\u2013413. https:\/\/doi.org\/10.11477\/mf.1416201779 (2021). Japanese.","journal-title":"Brain Nerve"},{"issue":"1","key":"85650_CR9","doi-asserted-by":"publisher","first-page":"16535","DOI":"10.1038\/s41598-019-52643-2","volume":"9","author":"YH Kim","year":"2019","unstructured":"Kim, Y. H. et al. Serum CXCL13 reflects local B-cell mediated inflammatory demyelinating peripheral neuropathy. Sci. Rep. 9(1), 16535. https:\/\/doi.org\/10.1038\/s41598-019-52643-2 (2019).","journal-title":"Sci. Rep."},{"issue":"1","key":"85650_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13075-018-1611-2","volume":"20","author":"E Armas-Gonz\u00e1lez","year":"2018","unstructured":"Armas-Gonz\u00e1lez, E. et al. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Res. Ther. 20(1), 114. https:\/\/doi.org\/10.1186\/s13075-018-1611-2 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"85650_CR11","doi-asserted-by":"publisher","first-page":"1129906","DOI":"10.3389\/fimmu.2023.1129906","volume":"14","author":"MJ Furman","year":"2023","unstructured":"Furman, M. J. et al. B cell targeted therapies in inflammatory autoimmune disease of the central nervous system . Front. Immunol. 14, 1129906. https:\/\/doi.org\/10.3389\/fimmu.2023.1129906 (2023).","journal-title":"Front. Immunol."},{"issue":"2","key":"85650_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2), 177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729 (2015). Epub 2015 Jun 19. PMID: 26092914; PMCID: PMC4515040.","journal-title":"Neurology"},{"issue":"2","key":"85650_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria . Lancet Neurol. 17(2), 162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2 (2018).","journal-title":"Lancet Neurol."},{"issue":"11","key":"85650_CR14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 33(11), 1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444 (1983).","journal-title":"Neurology"},{"issue":"9","key":"85650_CR15","doi-asserted-by":"publisher","first-page":"7960","DOI":"10.3390\/ijms24097960","volume":"24","author":"AW Khan","year":"2023","unstructured":"Khan, A. W. et al. Autoimmune Neuroinflammatory diseases: Role of interleukins . Int. J. Mol. Sci. 24(9), 7960. https:\/\/doi.org\/10.3390\/ijms24097960 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"85650_CR16","doi-asserted-by":"publisher","unstructured":"Zouali, M. et al. DNA methylation signatures of autoimmune diseases in human B lymphocytes. Clin. Immunol. 222, 108622. https:\/\/doi.org\/10.1016\/j.clim.2020.108622. [1 8 ], . Cancers (Basel). 2021;13(23):6132. doi: 10.3390\/cancers13236132. (2021).","DOI":"10.1016\/j.clim.2020.108622"},{"issue":"10","key":"85650_CR17","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ejphar.2019.172545","volume":"37","author":"AJ Henningsson","year":"2018","unstructured":"Henningsson, A. J., Lager, M.,  Br\u00e4nnstr\u00f6m, R. et al. The chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis. Eur. J. Clin. Microbiol. Infect. Dis. 37(10), 1983\u20131991. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172545 (2018).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"85650_CR18","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.3390\/cancers13236132","volume":"13","author":"T Matsuo","year":"2021","unstructured":"Matsuo, T.,  Yoshie, O., Nakayama, T. Multifaceted roles of chemokines and chemokine receptors in tumor immunity. Cancers (Basel). 13(23), 6132 https:\/\/doi.org\/10.3390\/cancers13236132.","journal-title":"Cancers (Basel)."},{"key":"85650_CR19","doi-asserted-by":"publisher","first-page":"172545","DOI":"10.1016\/j.ejphar.2019.172545","volume":"859","author":"E Kolanko","year":"2019","unstructured":"Kolanko, E. et al. Increased immunomodulatory capacity of human amniotic cells after activation by pro-inflammatory chemokines . Eur. J. Pharmacol. 859, 172545. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172545 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"85650_CR20","doi-asserted-by":"publisher","unstructured":"Pan, Z. et al. Role of the CXCL13\/CXCR5 axis in autoimmune diseases. Front Immunol. 13, 850998. https:\/\/doi.org\/10.3389\/fimmu.2022.850998 (2022). Erratum in: Front Immunol. 2022;13:1061939.","DOI":"10.3389\/fimmu.2022.850998"},{"issue":"8","key":"85650_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/23744235.2023.2222178","volume":"55","author":"D Sm\u00ed\u0161kov\u00e1","year":"2023","unstructured":"Sm\u00ed\u0161kov\u00e1, D. et al. Cerebrospinal fluid CXCL13 in non-borrelial central nervous system infections: Contribution of CXCL13 to the differential diagnosis. Infect. Dis. (Lond.) 55(8), 551\u2013558. https:\/\/doi.org\/10.1080\/23744235.2023.2222178 (2023).","journal-title":"Infect. Dis. (Lond)"},{"key":"85650_CR22","doi-asserted-by":"publisher","unstructured":"Leth, T. A. et al. Discriminating between Lyme neuroborreliosis and other central nervous system infections by use of biomarkers CXCL13 and IL-6. Ticks Tick Borne Dis. 13(5), 101984. https:\/\/doi.org\/10.1016\/j.ttbdis.2022.101984. (2022).","DOI":"10.1016\/j.ttbdis.2022.101984"},{"issue":"3","key":"85650_CR23","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.imbio.2020.151959","volume":"225","author":"M Yi","year":"2020","unstructured":"Yi, M. et al. Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders. Immunobiology 225(3), 151959. https:\/\/doi.org\/10.1016\/j.imbio.2020.151959 (2020).","journal-title":"Immunobiology"},{"issue":"3","key":"85650_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","volume":"28","author":"C Farina","year":"2007","unstructured":"Farina, C., Aloisi, F. & Meinl, E. Astrocytes are active players in cerebral innate immunity . Trends Immunol. 28(3), 138\u2013145. https:\/\/doi.org\/10.1016\/j.it.2007.01.005 (2007). Epub 2007 Feb 2. PMID: 17276138.","journal-title":"Trends Immunol."},{"issue":"9","key":"85650_CR25","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/1352458512473362","volume":"19","author":"E Alvarez","year":"2013","unstructured":"Alvarez, E. et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions . Mult Scler. 19(9), 1204\u20131208. https:\/\/doi.org\/10.1177\/1352458512473362 (2013). Epub 2013 Jan 15. PMID: 23322500; PMCID: PMC3959125.","journal-title":"Mult Scler."},{"issue":"2","key":"85650_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/jir.2012.0040","volume":"33","author":"KC Wang","year":"2013","unstructured":"Wang, K. C. et al. Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis. J. Interferon Cytokine Res. 33(2), 58\u201364. https:\/\/doi.org\/10.1089\/jir.2012.0040 (2013).","journal-title":"J. Interferon Cytokine Res."},{"issue":"1","key":"85650_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","volume":"266","author":"G Ellrichmann","year":"2019","unstructured":"Ellrichmann, G. et al. Peripheral CD19\u2009+\u2009B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders . J. Neurol. 266(1), 57\u201367. https:\/\/doi.org\/10.1007\/s00415-018-9092-4 (2019).","journal-title":"J. Neurol."},{"issue":"6","key":"85650_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s11064-021-03287-0","volume":"46","author":"P Zhang","year":"2021","unstructured":"Zhang, P., Sun, H. & Ji, Z. Downregulating lncRNA PVT1 relieves astrocyte overactivation induced neuropathic pain through targeting miR-186-5p\/CXCL13\/CXCR5 axis. Neurochem. Res. 46(6), 1457\u20131469. https:\/\/doi.org\/10.1007\/s11064-021-03287-0 (2021).","journal-title":"Neurochem. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85650-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:21:54Z","timestamp":1736965314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85650-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85650"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85650-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics Committee of Chenzhou First People\u2019s Hospital gave its approval for this research, in accordance with the Declaration of Helsinki. Signed informed consent were also obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"2113"}}